Over the past decade, immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have revolutionized the treatment of lung cancer (Antonia et al. 2018). This evidence concerns the gene PDCD1 and lung cancer.